NEW YORK, April 23, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Moments ago, Analysts Review released new research updates concerning several important developing situations including Asterias Biotherapeutics, Inc. (NYSEMKT: AST), Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), OncoMed Pharmaceuticals, Inc. (NASDAQ: OMED), Heron Therapeutics, Inc. (NASDAQ:HRTX), and The Providence Service Corporation. (NASDAQ: PRSC). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links below.
Today's update concerns the following companies:
Full PDF Download Links (you may have to copy and paste the following links into your browser):
AST Research Report: ( http://get.analystsreview.com/pdf/?c=Asterias&d=23-Apr-2015&s=AST ),
DRNA Research Report: ( http://get.analystsreview.com/pdf/?c=Dicerna&d=23-Apr-2015&s=DRNA ),
OMED Research Report: ( http://get.analystsreview.com/pdf/?c=OncoMed&d=23-Apr-2015&s=OMED ),
HRTX Research Report: ( http://get.analystsreview.com/pdf/?c=Heron&d=23-Apr-2015&s=HRTX ),
PRSC Research Report: ( http://get.analystsreview.com/pdf/?c=Providence%20Service%20Corporation&d=23-Apr-2015&s=PRSC ).
Events, Presentations, Progression of Clinical Trials, and Contracts
Analyst Update: Reviewed by: Rohit Tuli, CFA®
U.S. stocks edged higher on Wednesday as better than expected earnings and strong existing home sales data bolstered investor sentiment. The NASDAQ advanced 0.42% to finish at 5,035.17, its third straight gain and just 13 points below its record close reached on March 10, 2000. The Dow Jones Industrial Average rose 0.49% or 88.35 points to 18,038.27, and the S&P 500 gained 0.50%, or 9.69 points to close the session at 2107.96. European stocks closed with a mixed note on Wednesday, depressed by increasing concern over Greece's bailout negotiations and disappointing earnings. Germany's DAX and Britain's FTSE 100 index slipped 0.6% and 0.5%, respectively, while France's CAC gained 0.36% on Wednesday. Meanwhile, Asian market continued their good run with The Shanghai Composite and Japan's Nikkei closing at new multi-year highs on Wednesday.
Asterias Biotherapeutics, Inc. (Asterias) announced that the abstract describing long-term follow-up of patients with acute myelogenous leukemia (AML) from the Phase 2 clinical trial of the Company's autologous telomerase-based dendritic cell cancer vaccine, AST-VAC1, was selected for an oral presentation at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held in Chicago, Illinois May 29 - June 2, 2015.
Dicerna Pharmaceuticals, Inc. (Dicerna) has reported promising new in vivo data for CTNNB1 DsiRNA in multiple patient-derived xenograft (PDX) and other models of diverse tumor types. CTNNB1 DsiRNA is an extended Dicer substrate short interfering RNA (DsiRNA-EX) therapeutic targeting β-catenin and is delivered using Dicerna's proprietary next generation EnCore™ lipid nanoparticle (LNP) technology.
OncoMed Pharmaceuticals, Inc. (OncoMed) announced that the Company has presented seven posters highlighting its Clinical and Preclinical Anti-Cancer Stem Cell Programs at the American Association of Cancer Research (AACR) Annual Meeting.
On April 2, 2015, Heron Therapeutics, Inc. (Heron) announced that it has reached its enrollment target in MAGIC (Modified Absorption Granisetron In the Prevention of Chemotherapy induced nausea and vomiting (CINV)).
The Providence Service Corporation (Providence Service Corporation) announced that Mission Providence, its equity joint venture with Mission Australia was awarded with contracts from the Australian Department of Employment for the delivery of Employment Services across Australia for 5 year period ranging from 2015 to 2020.
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review